Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

Melia Blankenfeld, Danielle C. Kirkey, Guangyan Xiong, Hongbing Zhang, Grace Hawkins, Isabel Lira, Cyd McKay, Christina Root, Concetta Quintarelli, Franco Locatelli, Cheng Liu, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2024-206204

Published: 2024

Journal Articles

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

Tao Dao, Guangyan Xiong, Sung Soo Mun, Jeremy Meyerberg, Tatyana Korontsvit, Jingyi Xiang, Ziyou Cui, Aaron Y. Chang, Casey Jarvis, Winson Cai, Hanzhi Luo, Aspen Pierson, Anthony Daniyan, Sarah Yoo, Sumiko Takao, Michael Kharas, Alex Kentsis, Cheng Liu, David A. Scheinberg

Blood (2024) 143 (6): 507–521.

https://doi.org/10.1182/blood.2023021054

Published: 2024

Includes: Supplemental data

Journal Articles

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies

Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E. H. Aretz, Tanya Korontsvit, Michael Lau, Michael G. Kharas, Cheng Liu, David A. Scheinberg

Blood (2022) 140 (8): 861–874.

https://doi.org/10.1182/blood.2021012882

Published: 2022

Includes: Supplemental data

Journal Articles

Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Chenggong Li, Qi Chang, Jing Wang, Mengyi Du, Lin Liu, Haiming Kou, Cong Lu, Lu Tang, Jianghua Wu, Wenjing Luo, Yinqiang Zhang, Sha Ke, Jun Deng, Cheng Liu, Yu Hu, Heng Mei

Blood (2021) 138 (Supplement 1): 826.

https://doi.org/10.1182/blood-2021-152661

Published: 2021

Journal Articles

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

Martin G. Klatt, MD, Zhiyuan Yang, PhD, Jianying Liu, PhD, Tatyana Korontsvit, MD, Sung Soo Mun, Leila Peraro, PhD, Thomas J. Gardner, PhD, Christopher Bourne, Megan M. Dacek, Tao Dao, MD PhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140179

Published: 2020

Journal Articles

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Pengcheng He, Hong Liu, Haibo Liu, Mina Luo, Hui Feng, Qijing Li, Qi Chang, Bingyi Shi, Cheng Liu

Blood (2019) 134 (Supplement_1): 2870.

https://doi.org/10.1182/blood-2019-131414

Published: 2019

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

ET190L1-Artemis TM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma

Zhitao Ying, MD PhD, Li Long, MD PhD, Hong Liu, MD PhD, Yuqin Song, MD PhD, David A. Rizzieri, MD, Bijan Nejadnik, MD, Jun Zhu, MD PhD, Cheng Liu, PhD

Blood (2018) 132 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2018-99-113163

Published: 2018

Journal Articles

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Blood (2017) 130 (Supplement 1): 742.

https://doi.org/10.1182/blood.V130.Suppl_1.742.742

Published: 2017

Journal Articles

Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1813.

https://doi.org/10.1182/blood.V130.Suppl_1.1813.1813

Published: 2017

Journal Articles

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Sarwish Rafiq, PhD, Hollie J. Jackson, PhD, Oladapo Yeku, MD PhD, Terence J Purdon, MS, Dayenne G. van Leeuwen, Kevin J. Curran, MD, Ryan N Ahmed, Grace D Cullen, Su Yan, Pei Wang, PhD, Jingyi Xiang, Cheng Liu, PhD, Renier J. Brentjens, MD PhD

Blood (2017) 130 (Supplement 1): 842.

https://doi.org/10.1182/blood.V130.Suppl_1.842.842

Published: 2017

Journal Articles

Anti-CD19 ARTEMIS TM Therapy Drastically Reduces Cytokine Release without Compromising Efficacy Against Preclinical Lymphoma Models

Hong Liu, PhD, Li Long, MD PhD, Shon Green, PhD, Lucas H Horan, PhD, Bryan Zimdahl, PhD, Cheng Liu, PhD

Blood (2016) 128 (22): 3354.

https://doi.org/10.1182/blood.V128.22.3354.3354

Published: 2016

Journal Articles

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

Melissa D Mathias, MD, Jonathan T Sockolosky, PhD, Aaron Yu-Yuan Chang, BS, Cheng Liu, PhD, K. Christopher Garcia, PhD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4048.

https://doi.org/10.1182/blood.V128.22.4048.4048

Published: 2016

Journal Articles

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Aaron Chang, Tao Dao, PhD, Andrew Scott, Leonid Dubrovsky, MD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 2527.

https://doi.org/10.1182/blood.V126.23.2527.2527

Published: 2015

Journal Articles

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

Sarwish Rafiq, PhD, Tao Dao, MDPhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD, Renier J Brentjens, MD PhD

Blood (2014) 124 (21): 2155.

https://doi.org/10.1182/blood.V124.21.2155.2155

Published: 2014

Journal Articles

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL + leukemias

Leonid Dubrovsky, Dmitry Pankov, Elliott Joseph Brea, Tao Dao, Andrew Scott, Su Yan, Richard J O’Reilly, Cheng Liu, David A. Scheinberg

Blood (2014) 123 (21): 3296–3304.

https://doi.org/10.1182/blood-2014-01-549022

Published: 2014

Includes: Supplemental data

Journal Articles

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Dmitry Pankov, MD, Tao Dao, MD, PhD, Yiyang Wang, Andrew Scott, Tatyana Korontsvit, MD, Victoria Zakhaleva, Nicholas Veomett, Michael Curcio, Ekaterina Doubrovina, MD, PhD, Richard J. O'Reilly, MD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 2521.

https://doi.org/10.1182/blood.V122.21.2521.2521

Published: 2013

Journal Articles

Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors

Leonid Dubrovsky, MD, Elliott Brea, Dmitry Pankov, MD, Nicholas Veomett, Tao Dao, MD/PhD, Su Yan, PhD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 855.

https://doi.org/10.1182/blood.V122.21.855.855

Published: 2013

Journal Articles

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

Junli Yan, Siok-Bian Ng, Jim Liang-Seah Tay, Baohong Lin, Tze Loong Koh, Joy Tan, Viknesvaran Selvarajan, Shaw-Cheng Liu, Chonglei Bi, Shi Wang, Shoa-Nian Choo, Norio Shimizu, Gaofeng Huang, Qiang Yu, Wee-Joo Chng

Blood (2013) 121 (22): 4512–4520.

https://doi.org/10.1182/blood-2012-08-450494

Published: 2013

Includes: Supplemental data

Journal Articles

EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma

Wee-Joo Chng, Assoc/Prof, Junli Yan, PhD, Siok-Bian NG, Jim Tay, Ph.D., Baohong Lin, BSc, Tze-Loong Koh, B.sc., Joy Tan, BSc, Viknesvaran Selvarajan, Shaw-Cheng Liu, B.sc., Chonglei Bi, B.sc., Gaofeng Huang, PhD, Qiang Yu, Ph.D.

Blood (2012) 120 (21): 3498.

https://doi.org/10.1182/blood.V120.21.3498.3498

Published: 2012

NARROW

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies

Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

ET190L1-Artemis TM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma

Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade

Anti-CD19 ARTEMIS TM Therapy Drastically Reduces Cytokine Release without Compromising Efficacy Against Preclinical Lymphoma Models

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL + leukemias

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity

EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only